Skip to main content
Rapid Dose Therapeutics Corp logo

Rapid Dose Therapeutics Corp — Investor Relations & Filings

Ticker · DOSE ISIN · CA75339A1012 CSE Manufacturing
Open in API
Filings indexed 490 across all filing types
Latest filing 2024-03-25 Capital/Financing Update
Country CA Canada
Listing CSE DOSE

About Rapid Dose Therapeutics Corp

https://rapid-dose.com/

Rapid Dose Therapeutics Corp. is a pharma-technology company specializing in proprietary drug delivery technologies engineered to enhance patient outcomes and quality of life. The core business revolves around an innovative oral delivery platform utilizing sublingual thin film strip technology. The company's flagship product, QuickStrip™, is a fast-dissolving system designed for the rapid release of pharmaceuticals, micronized oils, and over-the-counter medicines. QuickStrip™ is distinguished by its ability to achieve blood concentrations comparable to intravenous injection, offering superior bioavailability and rapid onset. RDT provides product innovation, production, and consultation services to the pharmaceutical and healthcare manufacturing sectors for both prescription and non-prescription applications.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a proposed equity private placement financing and a proposed debt settlement by Rapid Dose Therapeutics Corp. It details the amount of financing, share price, use of proceeds, and terms of the debt settlement. There are no financial statements, detailed financial analysis, or comprehensive report content. The document is an update on capital raising activities and changes in capital structure rather than a full financial report or earnings release. It is not a regulatory filing or certification, nor is it a report publication announcement. The content fits best under Capital/Financing Update (CAP) as it provides information on fundraising and capital structure changes.
2024-03-25 English
News release - English.pdf
Regulatory Filings
2024-02-29 English
Material change report - English.pdf
Capital/Financing Update Classification · 95% confidence The document is titled 'FORM 51-102F3 MATERIAL CHANGE REPORT' and details the closing of two tranches of a private placement equity financing by Rapid Dose Therapeutics Corp. It includes specifics about the number of shares and warrants issued, the gross proceeds raised, commissions paid, and the intended use of proceeds. The document is a regulatory filing reporting a material change related to financing activities. It is not a full financial report, earnings release, or management discussion. It is not a proxy, AGM material, or legal proceeding. The content fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes. The document length (15,000 characters) and detailed content confirm it is the actual report, not just an announcement or certification. Therefore, the correct classification is CAP with high confidence.
2024-02-27 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 100% confidence The document is titled 'Form 45-106F1 Report of Exempt Distribution' and contains detailed information about a securities distribution, including issuer details, underwriter information, distribution dates, types of securities distributed, compensation information, and purchaser details. This form is a regulatory filing used to report exempt distributions of securities, typically filed with Canadian securities regulators. It is not an annual report, earnings release, or any other financial report but a specific regulatory disclosure related to securities distribution. The document is comprehensive and contains substantive data about the distribution event, fitting the category of a regulatory filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-02-26 English
News release - English.pdf
Capital/Financing Update Classification · 100% confidence The document is a press release announcing the closing of a second tranche of an equity private placement financing by Rapid Dose Therapeutics Corp. It details the amount raised, the securities issued, commissions paid, and the intended use of proceeds. There is no financial statement or detailed financial analysis present, only an update on financing activities. The document is not a full financial report, earnings release, or regulatory filing of financial results. It fits the category of Capital/Financing Update, as it provides information on fundraising and capital structure changes.
2024-02-26 English
News release - English.pdf
Regulatory Filings
2024-02-20 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.